#ESMO26 | Bulumtatug Fuvedotin – Phase II In metastatic TNBC previously treated with TOP1 inhibitor-based ADCs, the Nectin-4-targeted, MMAE-based ADC bulumtatug fuvedotin achieved an ORR of 30%, with a median PFS of 3.7 months. Changing both the target antigen and payload appears promising, although the relatively short PFS raises questions about the durability of benefit.